A rat study preparing for human trials for Parkinson's disease found that the no observed adverse effect level (NOAEL) dose was 6.8 × 108 viral genomes of an AAV2 vector encoding glial-derived neurotrophic factor administered as a single intracerebral dose into the striatum (Terse et al., 2021). This evidence concerns the gene GDNF and Parkinson disease.